Ziritaxestat
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02179502)
Timeline
Indications
Mechanism of action
- AutotaxinINHIBITOR
ENPP2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1- Mol. weight
- 588.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3828074 ↗
Also known as
- glpg1690
- glpg1690
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03976648 | Phase 2 | Jul 31, 2019 | Galapagos NV |
| NCT03798366 | Phase 2 | Jan 14, 2019 | Galapagos NV |
| NCT03711162 | Phase 3 | Nov 28, 2018 | Galapagos NV |
| NCT03787186 | Phase 1 | Nov 9, 2018 | Galapagos NV |
| NCT03733444 | Phase 3 | Nov 5, 2018 | Galapagos NV |
| NCT03515382 | Phase 1 | Mar 16, 2018 | Galapagos NV |
| NCT03143712 | Phase 1 | Apr 18, 2017 | Galapagos NV |
| NCT02738801 | Phase 2 | Mar 1, 2016 | Galapagos NV |
| NCT02179502 | Phase 1 | Jun 1, 2014 | Galapagos NV |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 9 | 9 | 3 | 2014 |
1 organizations
Page 1 / 1